Gilead announces preclinical results for TLR7 agonist GS-9620
25 February 2016 | By Victoria White
Data from the preclinical study support continued investigation of GS-9620 as part of an HIV eradication strategy…
List view / Grid view
25 February 2016 | By Victoria White
Data from the preclinical study support continued investigation of GS-9620 as part of an HIV eradication strategy…
6 May 2015 | By Victoria White
Gilead Sciences has acquired EpiTherapeutics, a scientific leader in the field of epigenetics with a library of first-in-class inhibitors, for $65 million.
25 July 2014 | By Gilead
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for Zydelig®...
24 July 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool to expand access to Gilead’s investigational drug tenofovir alafenamide...